Clinical trials: Non-Alcoholic Steatohepatitis (NASH)
Nonalcoholic Steatohepatitis (NASH)
Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH)
The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis (fatty liver disease) (NASH).
- Trial name
- NCT04267393
- Testing
- BMS-986263
- Where
- 112 sites in United States, Argentina and 14 more
- Volunteers
- 124 people
- Sponsor
- Bristol-Myers Squibb
NAFLD
The Effect of Consecutive Fecal Microbiota Transplantation on Non-Alcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic fatty liver disease (NAFLD) is a disease of alarmingly increasing prevalence, linked to metabolic, cardiovascular and malignant morbidity and without any officially approved treatment.
- Trial name
- NAFTx (NCT04465032)
- Testing
- Gut microbiome transplantation
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Leiden University Medical Center
Non Alcoholic Steatohepatitis
The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
To study the effects of Flaxseed supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in patients with Nonalcoholic Steatohepatitis (NASH), 50 patients who referred to Gastrointestinal (GI) clinic…
- Trial name
- NCT02395900
- Testing
- Flaxseed, control
- Volunteers
- 50 people
- Sponsor
- National Nutrition and Food Technology Institute
Non Alcoholic Steatohepatitis
Bariatric Surgery Versus Non-alcoholic Steato-hepatitis
Bariatric-metabolic surgery is effective in treating the cluster of conditions forming the metabolic syndrome, strictly associated with NAFLD and NASH.
- Trial name
- BRAVES (NCT03524365)
- Testing
- RYGB, SG, Intensive Lifestyle Modification
- Where
- 3 sites in Italy
- Volunteers
- 288 people
- Sponsor
- Catholic University of the Sacred Heart
Non Alcoholic Fatty Liver Disease
The Effect of Exercise Intervention on Insulin Resistance in Non-alcoholic Fatty Liver Disease (NAFLD)
This project examines the effects of a 4 month structured exercise intervention program in patients with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT01834300
- Testing
- Unsupervised exercise training, Supervised exercise training
- Where
- 7 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Liverpool
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections
Lifestyle, Dietary Patterns, and Cardiometabolic Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease Among People Living With HIV
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease, is an increasingly recognized comorbidity in people living with human immunodeficiency virus (HIV).
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), HIV Infections, Non-Alcoholic Fatty Liver Disease, Liver Cirrhosis
- Trial name
- NCT07861594
- Volunteers
- 250 people
- Sponsor
- Assiut University
Overweight and Obesity, Cardiovascular Diseases
Study Consortium for Evaluation of RNPC Program in Obese and Overweight Patients (SCOOP-RNPC)
The investigators hypothesize that weight loss obtained with the French RNPC weight reduction program is beneficial for the general health of overweight/obese patients in the medium term.
- Conditions
- Overweight and Obesity, Cardiovascular Diseases, Metabolic Disease, Diabete Type 2
- Trial name
- SCOOP-RNPC (NCT05857319)
- Testing
- Nutritional Psycho-Behavioral Reeducation Program
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Groupe Éthique et Santé
Nonalcoholic Steatohepatitis
Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis
The purpose of the study is to see if the drug colesevelam is a potential treatment for Nonalcoholic Steatohepatitis(NASH).
- Trial name
- NCT01066364
- Testing
- Colesevelam Hcl
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of California, San Diego
Non Alcoholic Steatohepatitis
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.
Patients of NASH (Non Alcoholic Steatohepatitis) cirrhosis with current or prior histological evidence of steatosis or steatohepatitis admitted under the Department of Hepatology at Institute of Liver and Biliary Sciences, who…
- Trial name
- NCT02721264
- Testing
- Fecal Microbiota Transplant, Standard Medical Treatment
- Where
- India
- Volunteers
- 112 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Disease
Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
The NAFLD Database 2 will recruit at least 1,500 new adult participants suspected or known to have NAFLD or nonalcoholic steatohepatitis (NASH)-related cirrhosis and will also invite adult participants from the prior NAFLD…
- Trial name
- NCT01030484
- Where
- 8 sites in United States
- Volunteers
- 2,501 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Exocrine Pancreatic Insufficiency, Fatty Liver, Nonalcoholic
Fatty Liver and Pancreatic Steatosis
The goal of this observational study is to determine the prevalence of pancreatic steatosis in patients with fatty liver and determine the prevalence of exocrine pancreatic insufficiency (EPI) in these patients.
- Conditions
- Exocrine Pancreatic Insufficiency, Fatty Liver, Nonalcoholic, Pancreatic Steatosis
- Trial name
- NCT06757348
- Testing
- Fecal elastase, Ecoendoscopy, Fibroscan
- Where
- Argentina
- Volunteers
- 61 people
- Sponsor
- Maria Marta Piskorz
Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease
Ultrasound Assessment of Sarcopenia in Patients With Chronic Liver Disease: the SARCOLIVER Study
Sarcopenia is a complex multifactorial syndrome which could be present in older age (primary sarcopenia) or earlier in chronic disease (secondary sarcopenia).
- Conditions
- Liver Cirrhosis, Non-Alcoholic Fatty Liver Disease, Hepatocellular Carcinoma
- Trial name
- SARCOLIVER (NCT06101758)
- Testing
- Handgrip strength test, total body Dual Energy X-Ray Absorptiometry (DXA), Muscle ultrasound
- Where
- Italy
- Volunteers
- 125 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Chronic Hepatitis B, Nonalcoholic Fatty Liver Disease
Clinical Effects of Ganshuang Combined TDF to Treat CHB and NAFLD
The changes in liver function, body mass index, controlled attenuation parameters, liver stiffness and HBV-DNA at different time points in each group before and after treatment were counted to explore the clinical efficacy of…
- Trial name
- NCT05523648
- Testing
- Chronic Hepatitis B
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Sichuan Leshan Traditional Chinese Medicine Hospital
Non-Alcoholic Steatohepatitis
The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis
The term non-alcoholic fatty liver disease (NAFLD) is used to describe a range of chronic liver diseases that range from steatosis to steatohepatitis, advanced fibrosis, cirrhosis, or excessive alcohol consumption or other causes…
- Trial name
- NCT05065593
- Testing
- resistance and aerobic exercise, physical activity recommendation
- Where
- Turkey (Türkiye)
- Volunteers
- 26 people
- Sponsor
- Hacettepe University
Overweight, Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
This is a multicenter, randomized, open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 9 mg QW versus Semaglutide 2.4 mg QW in overweight or obese (BMI≥27kg/m2) MAFLD subjects.
- Trial name
- NCT06884293
- Testing
- IBI362, semaglutide
- Where
- China
- Volunteers
- 479 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER
Evaluation of Multi-Organ Metabolism and Perfusion in Non-Alcoholic Fatty Liver Disease (NAFLD) by Total Body Dynamic PET Scan on EXPLORER
- Trial name
- EXPLORER (NCT04165343)
- Testing
- Positron Emission Tomography (PET) on EXPLORER, Magnetic Resonance Imaging, Echocardiogram and Electrocardiogram
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Overweight, Microtia
Demonstration of the Prebiotic-like Effects of Camu-camu Consumption Against Obesity-related Disorders in Humans
Previous work of the investigators demonstrated the anti-obesity and anti-steatosis potential of the Amazonian fruit camu-camu (CC) in a mouse model of diet-induced obesity [1].
- Conditions
- Overweight, Microtia, Endotoxemia, Metabolic Syndrome
- Trial name
- NCT04130321
- Testing
- Camu camu
- Where
- Canada
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Laval University
Non-Alcoholic Fatty Liver Disease, Liver Diseases
"CAP" Fetge Gras. Lifestyle Modification Program in Catalonia.
The main purpose of this study is to investigate whether an online lifestyle modification program for people with Metabolic Associated Fatty Liver Disease (MAFLD) through a mobile application produces a significant reduction in…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Diseases, Lifestyle, Healthy
- Trial name
- NCT04988633
- Testing
- Intervention CFG App, Control Group
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Hospital Clinic of Barcelona
Non-Alcoholic Fatty Liver Disease
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
- Trial name
- NCT04951219
- Testing
- Resmetirom
- Where
- 76 sites in United States, Puerto Rico
- Volunteers
- 810 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Thyroid Dysfunction, Metabolic Dysfunction-Associated Fatty Liver Disease
Thyroid Dysfunction and Its Association With Metabolic Dysfunction-Associated Fatty Liver Disease
This study aims to evaluate the prevalence of thyroid dysfunction and its association with metabolic dysfunction-associated fatty liver disease.
- Trial name
- NCT06739330
- Testing
- Fibroscan
- Where
- Egypt
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tanta University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.